N-allylisobutyramide | 4344-71-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-allylisobutyramide
• 英文别名: 2-methyl-N-prop-2-enylpropanamide
• CAS: 4344-71-2
• 化学式: C₇H₁₃NO
• mdl: MFCD03395474
• 分子量: 127.186
• InChiKey: KCDIHKAXKRTRMU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-allylisobutyramide 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 3.0h， 以88%的产率得到N-异丁基-2-丙烯-1-胺
  参考文献：
  名称：

  Preparation of 3-aza-Cope rearrangement of N-alkyl-N-allyl enamines

  摘要：

  The [3,3] charge-accelerated rearrangement of N-allyl-N-isobutyl enamine substrates to gamma,delta-unsaturated imine products and subsequent reduction to the corresponding N-alkyl delta,epsilon-unsaturated amines is reported. Several routes to the N-allyl-N-isobutyl enamines were established for the enamine prepared from isobutyraldehyde. With use of the most efficient route developed, enamines derived from butanal, 2-phenylpropanal, cyclohexanone, and cyclopentanone were prepared in 58 to 92% overall yield in three steps from allylamine. In the case of butanal, the E isomer was formed exclusively, while the enamine from 2-phenylpropanal was prepared with an E to Z selectivity of 86:14. Heating these N-allyl-N-isobutyl enamines in refluxing dioxane with 0.5 equiv of HCl produced [3,3] rearrangement for substrates derived from isobutyraldehyde, 2-phenylpropanal, and cyclohexanone; the enamines of n-butanal and cyclopentanone were found to react through alternate pathways.

  DOI：

  10.1021/jo00019a021
• 作为产物：
  描述：

  异丙基氯化镁 、 丙烯胺 在 氯甲酸苄酯 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 25.92h， 以58%的产率得到N-allylisobutyramide
  参考文献：
  名称：

  Amidation through carbamates

  摘要：

  N-Alkyl carbamates of primary amines are easily converted into amides under treatment with Grignard reagents. Consequently, primary amines call be converted into amides in a one-pot reaction through carbamate protection and Grignard addition. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2009.03.113

文献信息

• The extraordinary reactions of phenyldimethylsilyllithium with N,N-disubstituted amides
  作者：Marina Buswell、Ian Fleming、Usha Ghosh、Stephen Mack、Matthew Russell、Barry P. Clark

  DOI：10.1039/b412768d

  日期：——

  the text. Notably, each member of the homologous series of amides Ph(CH2)nCONMe2 gives rise to a substantially different product: when n= 0, the reaction is normal, and the yield of the alph]-silylamine 20e is high; when n=1, proton transfer in the intermediate anion 64 and displacement of the phenyl group leads to the silaindane 66; when n=2, fragmentation of the intermediate anion 80, and capture

  苯基二甲基甲硅烷基锂以各种方式与N，N-二甲基酰胺反应，具体取决于化学计量，温度以及最巧妙地取决于酰胺的结构，结构中似乎很小的变化导致其性质的深刻变化。产品。当将等摩尔量的甲硅烷基锂试剂和N，N-二甲基酰胺6在-78℃下在THF中混合，并将混合物在-78℃下淬灭时，产物是相应的酰基硅烷。如果在淬灭之前将同一混合物加热至-20摄氏度，则该产品为顺式二烯胺11。二烯胺容易从顺式异构化为反式，易氧化为二烯二胺，更难水解为α-氨基酮13。如果使用两当量的甲硅烷基锂试剂，则产物为α-甲硅烷基胺20。烯二胺的形成机理似乎是通过四面体中间体17的布鲁克重排，随后是硅烷氧化物的损失，从而得到卡宾或卡宾类物质。“卡宾”与布鲁克重排亲核试剂结合，得到中间体28，该中间体失去另一个硅烷氧化物离子，得到烯二胺。相同的卡宾可被第二当量的甲硅烷基锂试剂攻击，得到α-甲硅烷基胺20。其他亲核试剂，如烷基锂，苯基锂和三丁
• INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE
  申请人：WISCONSIN ALUMNI RESEARCH FOUNDATION

  公开号：US20170258805A1

  公开（公告）日：2017-09-14

  Compounds and salts thereof which are acyl-sulfonamides or certain carboxylic acids and which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include 2-aminothiazoles and triazolothiadiazines, particularly 3,6,7-substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 2-amino and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium , for example, M. tuberculosis and M. smegmatis and Klebsiella , for example, Klebsiella pneumoniae . Methods for inhibiting eukaryotic human and animal pathogens, and fungi and nematodes in particular. Methods for treatment of infections by prokaryotic and eukaryotic pathogens employing compounds of the invention.

  其酰基磺酰胺或某些羧酸的化合物及其盐，能够抑制微生物生长或减弱病原微生物的毒力，并且能够抑制UDP-半乳糖吡喃糖异构酶（UGM）。该发明的化合物包括2-氨基噻唑和三唑噻二嗪，特别是3,6,7-取代的7H-[1,2,4]三唑噻二嗪和其盐，以及2-氨基。抑制微生物病原体生长或减弱其毒力的方法包括结核分枝杆菌（例如结核分枝杆菌和平滑分枝杆菌）和克雷伯氏菌（例如肺炎克雷伯氏菌）等微生物病原体。抑制真核人类和动物病原体、真菌和线虫的方法，特别是治疗原核和真核病原体感染的方法，采用了该发明的化合物。
• Cp2TiCl2-Catalyzed reaction of grignard reagents with isocyanates, formation of carboxamide with rearranged carbonskeleton
  作者：Yongmin Zhang、Jinlong Jiang、Yongqian Chen

  DOI：10.1016/s0040-4039(00)96392-5

  日期：1987.1

  Isocyanates react with isopropyl or sec-butylmagnesium bromide in the presence of a small amount of Cp2TiCl2 to afford amides with normal alkyl group. A possibl mechanism for this reaction is proposed.

  异氰酸酯在少量Cp 2 TiCl 2存在下与异丙基或仲丁基溴化镁反应，得到具有正烷基的酰胺。提出了该反应的可能机理。
• Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors
  申请人：Niu Deqiang

  公开号：US20070299078A1

  公开（公告）日：2007-12-27

  The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及化合物，包括式I的化合物，或其药用可接受的盐、酯或前药：这些化合物抑制丝氨酸蛋白酶活性，特别是丝氨酸蛋白酶活性，尤其是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且还可用作抗病毒药剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• Quinoxalinyl tripeptide hepatitis C virus inhibitors
  申请人：Gai Yonghua

  公开号：US20080032936A1

  公开（公告）日：2008-02-07

  The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明涉及式I的化合物，或其药用可接受的盐、酯或前药，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。因此，本发明的化合物干扰了乙型肝炎病毒的生命周期，同时也可用作抗病毒药物。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者投与含本发明化合物的药物组合物来治疗HCV感染的方法。